Jeremy Skillington of Poolbeg: First time AI has been used to identify multiple disease targets in RSV
If you find this podcast useful please give it a rating and review on iTunes by clicking here
Jeremy Skillington, CEO of discusses the significant breakthrough in its Artificial Intelligence Programme, with partner OneThree Biotech Inc, through the discovery of multiple novel drug targets for the treatment of Respiratory Syncytial Virus.
Highlights
Following the completion of the build and optimisation of a tailored AI model in June 2022, the OneThree team, using its clinically validated AI platform, have identified novel drug targets using Poolbeg's unique RSV human challenge trial data.
The identification of these novel drug targets now allows the final stage of the programme to commence which will involve the identification of small molecule inhibitors to effectively treat RSV infections.
The team are particularly excited as these include a range of targets for which there are known drugs with existing Phase I safety and tolerability data. Prioritisation of compounds with existing Phase I data aligns with Poolbeg's capital light model as these compounds will have extensive nonclinical and clinical data allowing smooth transition to early human efficacy trials.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.